These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 25624048)

  • 1. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
    Martin SK; Gan ZY; Fitter S; To LB; Zannettino AC
    Leuk Res; 2015 Mar; 39(3):380-7. PubMed ID: 25624048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
    Gan ZY; Fitter S; Vandyke K; To LB; Zannettino AC; Martin SK
    Eur J Haematol; 2015 Apr; 94(4):343-54. PubMed ID: 25179233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (Buparlisib).
    Matas-Céspedes A; Rodriguez V; Kalko SG; Vidal-Crespo A; Rosich L; Casserras T; Balsas P; Villamor N; Giné E; Campo E; Roué G; López-Guillermo A; Colomer D; Pérez-Galán P
    Clin Cancer Res; 2014 Jul; 20(13):3458-71. PubMed ID: 24799524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance.
    Yu W; Chen Y; Xiang R; Xu W; Wang Y; Tong J; Zhang N; Wu Y; Yan H
    Leuk Lymphoma; 2017 Feb; 58(2):428-437. PubMed ID: 27439454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
    Sahin I; Azab F; Mishima Y; Moschetta M; Tsang B; Glavey SV; Manier S; Zhang Y; Sacco A; Roccaro AM; Azab AK; Ghobrial IM
    Am J Hematol; 2014 Nov; 89(11):1030-6. PubMed ID: 25060991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.
    Koul D; Fu J; Shen R; LaFortune TA; Wang S; Tiao N; Kim YW; Liu JL; Ramnarian D; Yuan Y; Garcia-Echevrria C; Maira SM; Yung WK
    Clin Cancer Res; 2012 Jan; 18(1):184-95. PubMed ID: 22065080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effect of two pan-class I PI3K inhibitors used as anticancer drugs on human T cell function.
    Blanco B; Herrero-Sánchez C; Rodríguez-Serrano C; Sánchez-Barba M; Del Cañizo MC
    Int Immunopharmacol; 2015 Sep; 28(1):675-85. PubMed ID: 26256696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance.
    Safaroghli-Azar A; Bashash D; Kazemi A; Pourbagheri-Sigaroodi A; Momeny M
    Eur J Pharmacol; 2019 Jan; 842():89-98. PubMed ID: 30401630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
    Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
    Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
    Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
    Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging.
    Wang S; Niu X; Bao X; Wang Q; Zhang J; Lu S; Wang Y; Xu L; Wang M; Zhang J
    Oncol Rep; 2019 May; 41(5):2636-2646. PubMed ID: 30896825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: Shedding new light on NVP-BKM120 mechanism of action.
    Bashash D; Safaroghli-Azar A; Delshad M; Bayati S; Nooshinfar E; Ghaffari SH
    Int J Biochem Cell Biol; 2016 Oct; 79():308-317. PubMed ID: 27599915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.
    Lonetti A; Antunes IL; Chiarini F; Orsini E; Buontempo F; Ricci F; Tazzari PL; Pagliaro P; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Barata JT; Martelli AM
    Leukemia; 2014 Jun; 28(6):1196-206. PubMed ID: 24310736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone.
    Zheng Y; Yang J; Qian J; Zhang L; Lu Y; Li H; Lin H; Lan Y; Liu Z; He J; Hong S; Thomas S; Shah J; Baladandayuthapani V; Kwak LW; Yi Q
    J Mol Med (Berl); 2012 Jun; 90(6):695-706. PubMed ID: 22207485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
    Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
    J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
    Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
    Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells.
    Ren H; Guo H; Thakur A; Zhang S; Wang T; Liang Y; Shi P; Gao L; Liu F; Feng J; Chen T; Yang T; Shang D; Liu JJ; Xu F; Chen M
    Oncotarget; 2016 Oct; 7(41):67277-67287. PubMed ID: 27572309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phosphatidylinositide 3-kinase inhibitor BKM120 suppresses proliferation and promotes apoptosis of U251 glioblastoma cells].
    Qiu Z; Yue S; Chang J; Wang G
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Jul; 32(7):936-9. PubMed ID: 27363276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis and management of myeloma bone disease.
    Christoulas D; Terpos E; Dimopoulos MA
    Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BKM120 induces apoptosis and inhibits tumor growth in medulloblastoma.
    Zhao P; Hall J; Durston M; Voydanoff A; VanSickle E; Kelly S; Nagulapally AB; Bond J; Saulnier Sholler G
    PLoS One; 2017; 12(6):e0179948. PubMed ID: 28662162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.